Stefan E. Schwartz

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment.

CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment.

Journal: Journal of hematology & oncology

Published: March 31, 2026

"Per aspera ad astra": the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high-dose therapy.

"Per aspera ad astra": the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high-dose therapy.

Journal: Expert review of hematology

Published: March 10, 2026

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Journal: Cancers

Published: February 26, 2026

Plant Phenomics-the unrecognized rise of a scientific discipline.

Plant Phenomics-the unrecognized rise of a scientific discipline.

Journal: Trends in plant science

Published: February 24, 2026

Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient.

Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient.

Journal: The oncologist

Published: December 23, 2025

Molecular diagnostics in cancer patients with suspected respiratory mold infections.

Molecular diagnostics in cancer patients with suspected respiratory mold infections.

Journal: Journal of clinical microbiology

Published: November 26, 2025

High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.

High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.

Journal: Cancers

Published: November 26, 2025

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Journal: Blood neoplasia

Published: September 24, 2025

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

Journal: Blood

Published: August 04, 2025

IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

Journal: Blood

Published: August 04, 2025

Retraction Note: New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid.

Retraction Note: New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid.

Journal: Cancer chemotherapy and pharmacology

Published: July 25, 2025

Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy.

Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy.

Journal: Blood cancer journal

Published: June 03, 2025

Showing 1-12 of 93

Last Updated: 09/26/2026